This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Andrew Butcher describes why securing stakeholder buy-in to high-cost new therapies is critical to managing the pharmaceutical industry’s reputation in the November/December 2015 issue of PharmaVOICE. To read more, click here.
A new report from the Partnership for Health System Sustainability and Resilience EU Expert Advisory Group, supported by CRA, calls for a more strategic and...
In the first of a new series of CRA Insights on this topic, Aaron Everitt looks at how Keytruda and other branded and biosimilar manufacturers are preparing...
CRA is a proud sponsor of the conference that aims to increase the prominence of women through professional development, substantive legal discussion, and...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
